LONDON (Reuters) - GlaxoSmithKline's top-selling respiratory drug Advair is set to lose business to Spiriva, marketed by Pfizer and Boehringer Ingelheim, according to analysts at Morgan Stanley. Sign ...
LONDON, March 16 (Reuters) - Adding GlaxoSmithKline Plc's top-selling drug Advair to Pfizer Inc's Spiriva does not reduce exacerbations in patients with COPD, or smoker's lung, according to new ...
Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows GSK (GlaxoSmithKline) logo (Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap ...
Advair is used to treat asthma and chronic obstructive pulmonary disease. The Association for Accessible Medicines is voicing strong opposition that the proposed U.S.-Mexico-Canada trade agreement ...
October 27, 2006 (Salt Lake City) -- New findings from the landmark Towards a Revolution in COPD Health (TORCH) study show that high-dose inhaled fluticasone propionate 500 mg/salmeterol 50 mg ( ...
Inhalers like Spiriva and Advair are too expensive for many Medicare beneficiaries with chronic obstructive pulmonary disease, reports Kaiser Health News. Here are four things to know. 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results